August 11, 2017 / 9:57 PM / 11 days ago

BRIEF-Soleno Therapeutics reports Q2 loss/share of $0.07

Aug 11 (Reuters) - Soleno Therapeutics Inc

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

* Soleno - To begin phase iii program by end of year for DCCR in Prader-Willi Syndrome ​

* Q2 loss per share $0.06 from continuing operations

* Q2 loss per share $0.07 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below